Priorix Market Report 2026

Priorix Market Overview

• The Priorix market growth in the historic period has been driven by global adoption of mmr vaccination schedules, declining measles and rubella incidence rates • Market expansion is supported by increasing focus on disease eradication goals, rising investments in vaccine supply resilience • Growth Driver: Rising Prevalence Of Mumps Fuels Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Priorix Market?

Priorix is a combination vaccine used to protect against three infectious diseases namely measles, mumps, and rubella (MMR). It contains live, attenuated viruses of these diseases, which stimulate the immune system to provide immunity. Typically administered as a subcutaneous or intramuscular injection, Priorix is given in two doses, the first at 12–15 months of age and the second around 4–6 years, depending on national immunization schedules. The main formulations of priorix are lyophilized (freeze-dried) and liquid. Lyophilized vaccines are freeze-dried formulations designed to maintain stability and extend shelf life under specific conditions. The indications are measles, mumps, and rubella, and the age group includes infants (0-12 months) and children (1-5 years). It is used by various end users, such as pediatric patients and healthcare providers.

What Is The Priorix Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on disease eradication goals, rising investments in vaccine supply resilience, expansion of immunization access in emerging economies, improved vaccine formulation stability, growing emphasis on outbreak prevention. Major trends in the forecast period include expansion of pediatric immunization coverage, growing emphasis on combination vaccines, improved vaccine cold chain management, rising public health awareness campaigns, strengthening of national immunization programs.

What Are The Drivers Of The Priorix Market?

The rise in the prevalence of mumps is expected to propel the priorix market going forward. Mumps is a contagious viral infection characterized by painful swelling of the salivary glands, particularly the parotid glands, located below the ears. The rise in mumps prevalence is driven by waning immunity from childhood vaccinations, insufficient vaccine coverage, and increased outbreaks in crowded settings such as schools and colleges. Priorix is used to prevent mumps by providing active immunization against the mumps virus as part of a combination vaccine. It stimulates the immune system to produce antibodies, reducing infection risk and curbing outbreaks. For instance, in December 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the total number of mumps cases in the US in 2022 was 386, which reached 436 in 2023. Therefore, the rise in the prevalence of mumps drives the priorix industry. The rise in healthcare expenditure is expected to propel the priorix market going forward. Healthcare expenditure refers to the total amount of financial resources spent on medical services, healthcare infrastructure, pharmaceuticals, and healthcare-related activities. Healthcare expenditure is rising due to factors such as higher operational costs in healthcare facilities, increasing prevalence of chronic and lifestyle-related diseases, rise in prevalence of genetic disorders, advances in medical technology, and greater access to healthcare services. Increasing healthcare expenditure supports the widespread use of priorix by improving access to vaccination programs and helping prevent measles, mumps, and rubella in vulnerable populations. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the increase in healthcare expenditure drives the priorix industry. The rising government immunization programs are expected to propel the Priorix market going forward. Government immunization programs refer to organized initiatives by a government to provide vaccines to a population, aiming to prevent the spread of infectious diseases and protect public health. Rising government immunization programs are primarily due to the growing need to prevent the spread of infectious diseases and protect public health. Rising government immunization programs support the uptake of Priorix by increasing access to and awareness of vaccines, thereby driving broader protection against measles, mumps, and rubella in target populations. For instance, in June 2023, according to the UK Health Security Agency, a UK-based government agency, from 2022 to 2023, a total of 3,502,566 children, spanning from Reception to Year 9, were vaccinated under the school-aged vaccination program. Therefore, the rising government immunization programs drive the Priorix industry.

Key Players In The Global Priorix Market

Major companies operating in the priorix market are GSK plc

What Defines the Priorix Market?

The priorix market consists of sales of pre-filled vials, diluents, and delivery kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Priorix Market Report 2026?

The priorix market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the priorix industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.